Growth Factor News and Research

RSS

Ortho-Clinical Diagnostics announces availability of NEPHROCHECK Test System for AKI patients

Ortho-Clinical Diagnostics, Inc. today announced the nationwide availability to hospitals of the NEPHROCHECK Test System designed to help healthcare providers identify patients at risk of developing moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment.

From Ortho-Clinical Diagnostics, Inc. 16 Dec 2014

Joslin study could lead to improved anti-aging drugs

In a study published today by Nature, researchers at Joslin Diabetes Center used a microscopic worm (C. elegans) to identify a new path that could lead to drugs to slow aging and the chronic diseases that often accompany it--and might even lead to better cosmetics.

16 Dec 2014

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target.

16 Dec 2014

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

16 Dec 2014

Trastuzumab drug improves long-term survival of patients with HER-2 positive breast cancer

VCU Massey Cancer Center physician-researcher Charles E. Geyer, Jr., M.D., was the National Protocol Officer for one component of a large national study involving two National Cancer Institute-supported clinical trials that demonstrated that trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients.

16 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report.

15 Dec 2014

Study sheds light on clinical and biological characteristics of male breast cancer

Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women.

14 Dec 2014

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows.

12 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

12 Dec 2014

OCT enhances neovascular subtype detection in AMD

Researchers recommend the inclusion of optical coherence tomography anatomic classification with fluorescein angiography grading to identify initial neovascular lesion subtypes in newly diagnosed age-related macular degeneration.

11 Dec 2014

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations.

11 Dec 2014

CUMC researchers devise way to replace torn knee meniscus

Columbia University Medical Center researchers have devised a way to replace the knee's protective lining, called the meniscus, using a personalized 3D-printed implant, or scaffold, infused with human growth factors that prompt the body to regenerate the lining on its own.

11 Dec 2014

Use of HF-WBI for patients with early-stage breast cancer increases 17.4%, study finds

The use of hypofractionated whole-breast irradiation (HF-WBI) for patients with early-stage breast cancer increased 17.4 percent from 2004 to 2011, and patients are more likely to receive HF-WBI compared to conventionally fractionated whole-breast irradiation (CF-WBI) when they are treated at an academic center or live ≥50 miles away from a cancer center, according to a study published in the December 1, 2014 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology.

10 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

Researchers gain new insights into potential treatment for Alzheimer's disease

It is estimated that about 35 million people worldwide currently suffer from dementia and it is expected that the number will increase to 135 million by the year 2050. The disease is already one of the most common health problems in the elderly, which is why experts predict that the numbers of people affected will increase over time.

8 Dec 2014

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.

4 Dec 2014

Researchers identify possible prognostic biomarker in triple-negative breast cancer

"Triple-negative" breast cancer (TNBC) occurs in patients whose cells do not express receptors for estrogen, progesterone, and/or human epidermal growth factor receptor 2 (ER-/PR-/HER2-).

2 Dec 2014

New therapeutic targets can prevent scarring within transplanted kidneys

Kidneys donated by people born with a small variation in the code of a key gene may be more likely, once in the transplant recipient, to accumulate scar tissue that contributes to kidney failure, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Journal of Clinical Investigation.

2 Dec 2014

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences.

2 Dec 2014

Growth Factor News and Research

Ortho-Clinical Diagnostics announces availability of NEPHROCHECK Test System for AKI patients

Joslin study could lead to improved anti-aging drugs

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Trastuzumab drug improves long-term survival of patients with HER-2 positive breast cancer

Postoperative recurrent disease affects NSCLC survival after gefitinib

Study sheds light on clinical and biological characteristics of male breast cancer

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Postoperative recurrent disease affects NSCLC survival after gefitinib

OCT enhances neovascular subtype detection in AMD

First-line dacomitinib may improve advanced NSCLC survival

CUMC researchers devise way to replace torn knee meniscus

Use of HF-WBI for patients with early-stage breast cancer increases 17.4%, study finds

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

PD-1, PD-L1 differentially expressed in NSCLC

Researchers gain new insights into potential treatment for Alzheimer's disease

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Researchers identify possible prognostic biomarker in triple-negative breast cancer

New therapeutic targets can prevent scarring within transplanted kidneys

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Latest News